Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blood clot in the lungs be treated at home? new study investigates

NCT ID NCT07506291

Symptom relief Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with a moderate-risk blood clot in the lungs can be safely treated at home instead of staying in the hospital. About 568 adults will be randomly assigned to either go home early or receive standard hospital care. The goal is to see if home treatment is just as safe and improves quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 568 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presentation to the Emergency Department or unscheduled consultation in one of the participating centers * Symptomatic PE objectively confirmed according to the European Society of Cardiology criteria 4 (either by i) a high-probability ventilation/perfusion lung scan, ii) a new contrast filling defect on spiral computed tomography, or iii) a new documentation by ultrasonography of a proximal DVT, i.e., thrombus in the popliteal vein or above, along with clinical signs of PE. All radiological tests used to diagnose PE will be interpreted by on-site radiologists or angiologists) * No clinical criteria mandating hospitalization according to the Hestia rule, i.e., negative Hestia rule * Right ventricular dysfunction - defined as a right ventricular (RV) to left ventricular (LV) diameter ratio \> 1.0 on echocardiography (apical four-chamber or subcostal four-chamber view) or on CTPA (transverse plane) OR High-sensibility cardiac troponin I or T concentration above the upper limit of local normal value * Insurance cover according to local legislation * Age ≥18 years * Signed free informed consent (or oral consent if possible according to local regulation). Exclusion Criteria: * Shock or hypotension (defined as systolic blood pressure \<90 mmHg or a systolic pressure drop by ≥40 mmHg, for \>15 minutes, if not caused by new-onset arrhythmia, hypovolemia, or sepsis) * Combined right ventricular dysfunction (RV/LV \> 1.0 on imaging) AND troponin concentration above the upper limit of local normal value * Free floating thrombi in the right atrium or ventricle, if identified by routine echocardiography or CTPA * Active cancer other than basal or squamous-cell skin cancer defined at least with one of the following: i) cancer diagnosed within the last 6 months, ii) current anti-cancer treatment or during the 6 months before enrollment, iii) locally advanced or metastatic cancer * PE diagnosis established since more than 24 hours * 48 hours or more elapsed between ED presentation and potential inclusion or other reason making home discharge impossible within the 48 hours since ED presentation * Limited life expectancy or any other reason making 3-month follow-up impossible * Pregnant or parturient patient * Patient in detention by judicial or administrative decision, under a legal protection measure or undergoing compulsory psychiatric treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pulmonary embolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism Ventricular Dysfunction, Right

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pulmonary embolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Angers University Hospital, Emergency Department

    Angers, 49000, France

  • Argenteuil hospital, Emergency department

    Argenteuil, 95100, France

  • Brest University Hospital (site Cavale Blanche), Cardiology Department

    Brest, 29200, France

  • Cholet Hospital, Emergency department

    Cholet, 49300, France

  • Clermont-Ferrand University Hospital, Emergency department

    Clermont-Ferrand, 63000, France

  • Grenoble University Hospital, Emergency Department

    Grenoble, 38000, France

  • Le Mans Hospital, Emergency department

    Le Mans, 72000, France

  • Lyon University Hospital (site Edouard Herriot), Emergency Department

    Lyon, 69003, France

  • Lyon University Hospital (site Lyon Sud), Emergency department

    Pierre-Bénite, 69495, France

  • Nantes University Hospital, Emergency department

    Nantes, 44000, France

  • Paris University Hospital (APHP - site HEGP), Emergency Department

    Paris, 75015, France

  • Paris University Hospital (APHP - site La Pitié-Salpétrière Hospital), Emergency Department

    Paris, 75013, France

  • Paris University Hospital (APHP - site Lariboisière hospital), emergency department

    Paris, 75010, France

  • Paris University Hospital (APHP - site Louis Mourier), Emergency Department

    Colombes, France

  • Paris University Hospital (APHP, site Hôpital Européen Georges Pompidou), Pneumology department

    Paris, France

  • Poitiers University Hospital, Emergency Department

    Poitiers, 86000, France

  • Rouen University Hospital, Emergency Department

    Rouen, 76000, France

  • Toulouse University Hospital, Emergency Department

    Toulouse, 31000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.